Alnylam Pharmace. buy BiotechBee
Summary
This prediction is currently active. The prediction currently has a performance of 15.90%. This prediction currently runs until 31.12.24. The prediction end date can be changed by BiotechBee at any time. BiotechBee has 70% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
Name | 1w | 1m | 1y |
---|---|---|---|
Alnylam Pharmace. | -0.853% | -0.853% | 44.097% |
iShares Core DAX® | -1.114% | 5.062% | 24.922% |
iShares Nasdaq 100 | 1.816% | 9.828% | 29.548% |
iShares Nikkei 225® | 2.113% | 8.218% | 22.231% |
iShares S&P 500 | 2.038% | 7.448% | 30.358% |
According to BiotechBee what are the pros and cons of Alnylam Pharmace. for the foreseeable future?
Pros
Cons
Comments by BiotechBee for this prediction
In the thread Alnylam Pharmace. diskutieren